Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             72 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Aberrant DNA methylation of the transcription factor C/EBPα in acute myelogenous leukemia Jost, Edgar
 2009
 33 Supplement 2 p. 443-449
7 p.
 artikel
2 Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms Hopfer, Olaf
 2009
 33 Supplement 2 p. 434-442
9 p.
 artikel
3 Aberrant somatic hypermutations in thyroid lymphomas Takakuwa, Tetsuya
 2009
 33 Supplement 2 p. 649-654
6 p.
 artikel
4 Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia Hatzimichael, Eleftheria
 2009
 33 Supplement 2 p. 1272-1275
4 p.
 artikel
5 Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL? Valera, Elvis Terci
 2009
 33 Supplement 2 p. e139-e142
nvt p.
 artikel
6 Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes Satoh, Chikako
 2009
 33 Supplement 2 p. 326-331
6 p.
 artikel
7 40 Allogeneic stem cell transplantation in MDS: reduced intensity conditioning and donor lymphocyte infusion Kröger, N.
 2009
 33 Supplement 2 p. S28-
1 p.
 artikel
8 Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal Breccia, M.
 2009
 33 Supplement 2 p. 391-394
4 p.
 artikel
9 A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial Chevallier, Patrice
 2009
 33 Supplement 2 p. 1124-1126
3 p.
 artikel
10 A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome Kim, Hawk
 2009
 33 Supplement 2 p. 222-231
10 p.
 artikel
11 A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid Ryningen, Anita
 2009
 33 Supplement 2 p. 779-787
9 p.
 artikel
12 A tumour stage-dependent evolution of drug resistant T cell lymphoma: Role of soluble mediators of tumour and host origin Singh, Vivek
 2009
 33 Supplement 2 p. 700-709
10 p.
 artikel
13 6 BMI-1 and AML1 point mutation in the pathogenesis of MDS Kimura, A.
 2009
 33 Supplement 2 p. S2-S3
2 p.
 artikel
14 Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience Zheng, Weiyan
 2009
 33 Supplement 2 p. 1615-1618
4 p.
 artikel
15 Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia Rogalinska, Malgorzata
 2009
 33 Supplement 2 p. 308-314
7 p.
 artikel
16 C002 C-type lectin-like molecule-1 (CLL-1) and lineage infidelity marker expression as assessed by flow cytometry distinguishes normal and aberrant stem cells in myelodysplastic syndromes Westers, T.
 2009
 33 Supplement 2 p. S31-S32
2 p.
 artikel
17 CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia Xu, Wei
 2009
 33 Supplement 2 p. 237-243
7 p.
 artikel
18 C016 Expression analysis of proteins involved in the Non Homologous End Joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes Economopoulou, P.
 2009
 33 Supplement 2 p. S40-S41
2 p.
 artikel
19 c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D Chen-Deutsch, Xiangwen
 2009
 33 Supplement 2 p. 1372-1378
7 p.
 artikel
20 C030 Long-term remission of post-transplant MDS/AML by adoptive transfer of allogeneic WT1-specific CD4+ and CD8+ T lymphocytes Kim, Y.
 2009
 33 Supplement 2 p. S49-
1 p.
 artikel
21 Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes Wang, Rong
 2009
 33 Supplement 2 p. 1594-1598
5 p.
 artikel
22 C033 Quantification of phosphoinositidephospholipase C (PI-PLC) beta 1 gene promoter methylation predicts the responsiveness to azacitidine in myelodysplastic syndromes Follo, M.
 2009
 33 Supplement 2 p. S51-
1 p.
 artikel
23 Decitabine treatment of patients with higher-risk myelodysplastic syndromes Steensma, David P.
 2009
 33 Supplement 2 p. S12-S17
6 p.
 artikel
24 Demethylating agent 5-aza-2′-deoxycytidine activates HLA-G expression in human leukemia cell lines Poláková, K.
 2009
 33 Supplement 2 p. 518-524
7 p.
 artikel
25 Editorial Board 2009
 33 Supplement 2 p. CO2-
1 p.
 artikel
26 GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism Zhang, Su-Jiang
 2009
 33 Supplement 2 p. 1141-1143
3 p.
 artikel
27 Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia Chang, Hong
 2009
 33 Supplement 2 p. 259-262
4 p.
 artikel
28 Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor Imai, Norikazu
 2009
 33 Supplement 2 p. 1650-1657
8 p.
 artikel
29 Haemorrhagic complications associated with reduced α2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia Matsue, Kosei
 2009
 33 Supplement 2 p. 867-869
3 p.
 artikel
30 2-(1-Hydroxethyl)-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophene-4,8-dione (BTP-11) enhances the ATRA-induced differentiation in human leukemia HL-60 cells Chen, Chun-Jen
 2009
 33 Supplement 2 p. 1664-1669
6 p.
 artikel
31 Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents Silverman, Lewis R.
 2009
 33 Supplement 2 p. S18-S21
4 p.
 artikel
32 Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts Cermak, Jaroslav
 2009
 33 Supplement 2 p. 1469-1474
6 p.
 artikel
33 Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity Hoshi, Masato
 2009
 33 Supplement 2 p. 39-45
7 p.
 artikel
34 Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents De la Iglesia Iñigo, Silvia
 2009
 33 Supplement 2 p. 810-816
7 p.
 artikel
35 In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia Lönnerholm, Gudmar
 2009
 33 Supplement 2 p. 46-53
8 p.
 artikel
36 John Auer and Auer rods; controversies revisited Yoshida, Yataro
 2009
 33 Supplement 2 p. 614-616
3 p.
 artikel
37 JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C) Shami, Paul J.
 2009
 33 Supplement 2 p. 1525-1529
5 p.
 artikel
38 Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia Neumann, Frank
 2009
 33 Supplement 2 p. 232-236
5 p.
 artikel
39 Many are called MDS cell lines: One is chosen Drexler, Hans G.
 2009
 33 Supplement 2 p. 1011-1016
6 p.
 artikel
40 Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients Sar, Aylin
 2009
 33 Supplement 2 p. 792-797
6 p.
 artikel
41 New insights into the role of the tuberous sclerosis genes in leukemia Rosner, Margit
 2009
 33 Supplement 2 p. 883-885
3 p.
 artikel
42 Non-hemic autoimmunity in CLL Hamblin, Terry J.
 2009
 33 Supplement 2 p. 366-367
2 p.
 artikel
43 OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus Våtsveen, Thea Kristin
 2009
 33 Supplement 2 p. 1670-1677
8 p.
 artikel
44 P046 Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes Karadonat, A.
 2009
 33 Supplement 2 p. S85-
1 p.
 artikel
45 P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome Oliva, E.
 2009
 33 Supplement 2 p. S103-
1 p.
 artikel
46 P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes de Castro, C.
 2009
 33 Supplement 2 p. S137-
1 p.
 artikel
47 P055 Cyclooxygenase-2 is overexpressed in del5q myelodysplastic syndromes Shapiro, R.
 2009
 33 Supplement 2 p. S90-S91
2 p.
 artikel
48 P005 Data from the registry of the patients with myelodysplastic syndrome from Clinic of Hematology, Fundeni Clinical Institute, Bucharest, Romania. V. A comparative analysis: from FAB to WHO classification Vasilache, D.
 2009
 33 Supplement 2 p. S60-S61
2 p.
 artikel
49 P120 Decitabine in myelodysplastic syndromes, 18 months of follow up: Argentine initial multi-institutional clinical experience Iastrebner, M.
 2009
 33 Supplement 2 p. S129-
1 p.
 artikel
50 P063 DNA damage in peripheral blood cells of MDS patients Watson, D.
 2009
 33 Supplement 2 p. S95-S96
2 p.
 artikel
51 Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma Farag, Sherif S.
 2009
 33 Supplement 2 p. 1475-1480
6 p.
 artikel
52 P094 Impact of an educational program at the onset of new therapy (hypomethylating agent) in myelodysplastic syndromes: a pilot study with positive effects on both patients and physicians Moulis, G.
 2009
 33 Supplement 2 p. S114-
1 p.
 artikel
53 P032 Karyotypic complexity and multiclonality: two cytogenetic parameters to be considered in MDS prognostic evaluation Gourgouveli, E.
 2009
 33 Supplement 2 p. S77-
1 p.
 artikel
54 P110 Lenalidomide in low and int-1 risk MDS with del5q: efficacy and quality of life Oliva, E.
 2009
 33 Supplement 2 p. S123-
1 p.
 artikel
55 P080 Myelodysplastic syndromes (MDS): factors increasing probability for leukaemic transformation in a Greek series of patients from a single institution Diamantidis, M.
 2009
 33 Supplement 2 p. S104-
1 p.
 artikel
56 24 PNH: new options Hill, A.
 2009
 33 Supplement 2 p. S20-S21
2 p.
 artikel
57 P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia Such, E.
 2009
 33 Supplement 2 p. S74-S75
2 p.
 artikel
58 P021 Prognostic significance of beta 2 microglobulin predicting survival in patients with myelodysplastic syndromes Galanopoulos, A.
 2009
 33 Supplement 2 p. S70-
1 p.
 artikel
59 Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia Tavernier-Tardy, Emmanuelle
 2009
 33 Supplement 2 p. 764-768
5 p.
 artikel
60 Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature Paydas, Semra
 2009
 33 Supplement 2 p. 1627-1635
9 p.
 artikel
61 PTEN deficiency is a common defect in juvenile myelomonocytic leukemia Liu, Yunying Lucy
 2009
 33 Supplement 2 p. 671-677
7 p.
 artikel
62 P019 Time changes in predictive power of established and recently proposed clinical, cytogenetic, and co-morbidity scores in MDS Tuechler, H.
 2009
 33 Supplement 2 p. S68-S69
2 p.
 artikel
63 P107 Treatment of MDS with moderate anemia, not requiring RBC transfusions, by erythropoiesis stimulating agents (ESAs) Park, S.
 2009
 33 Supplement 2 p. S122-
1 p.
 artikel
64 Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation Lim, Z.Y.
 2009
 33 Supplement 2 p. 244-249
6 p.
 artikel
65 Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes Fenaux, Pierre
 2009
 33 Supplement 2 p. S7-S11
5 p.
 artikel
66 Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia Poyer, Florent
 2009
 33 Supplement 2 p. 407-417
11 p.
 artikel
67 Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia Park, Tae Sung
 2009
 33 Supplement 2 p. 1001-1004
4 p.
 artikel
68 The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study Truong, Francoise
 2009
 33 Supplement 2 p. 1039-1046
8 p.
 artikel
69 Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells Chen, Jing-Yi
 2009
 33 Supplement 2 p. 1520-1524
5 p.
 artikel
70 Unbalanced whole-arm translocation der(5;19)(p10;q10) is a novel and recurrent cytogenetic aberration in myelodysplastic syndrome Yamamoto, Katsuya
 2009
 33 Supplement 2 p. 377-383
7 p.
 artikel
71 Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell? Tabaczewski, Piotr
 2009
 33 Supplement 2 p. 854-855
2 p.
 artikel
72 ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells Jia, Hong-Yun
 2009
 33 Supplement 2 p. 1512-1519
8 p.
 artikel
                             72 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland